An experimental drug known as lepodisiran has been discovered to significantly reduce levels of lipoprotein(a) (Lp(a)), a cholesterol-like particle associated with an increased risk of heart attacks and strokes. This new research, conducted by Cleveland Clinic and published in The New England Journal of Medicine, has found that lepodisiran can silence the gene responsible for synthesizing Lp(a), making it a promising treatment option for the millions of people worldwide with elevated levels of this particle.
Lp(a) is an independent risk factor for heart disease that is largely determined by genetics, unlike traditional cholesterol which is influenced by lifestyle factors. Unlike LDL, which can be lowered with medications, currently there are no approved treatments available to target Lp(a). The study performed a clinical trial involving 320 individuals globally, showing a nearly 100% reduction in Lp(a) levels after just one injection of lepodisiran.
However, while the initial results are promising, further testing is needed to determine if the reduction in Lp(a) levels translates into a lower risk of heart attacks and strokes. The phase 3 trial to address this question is already underway, with researchers also enrolling more Black participants to address the lack of diversity in the current study population.
Despite these limitations, the findings of this research may offer hope for millions of people at risk of heart disease due to elevated Lp(a) levels. Experts recommend that all adults check their Lp(a) levels, as this genetic risk factor remains virtually unchanged over time. With further research and clinical trials, lepodisiran could potentially fill the gap in treating a previously untreatable cardiovascular risk.
Note: The image is for illustrative purposes only and is not the original image associated with the presented article. Due to copyright reasons, we are unable to use the original images. However, you can still enjoy the accurate and up-to-date content and information provided.
